Reckitt Benckiser Company Profile
What is the competitive landscape for RECKITT BENCKISER
RECKITT BENCKISER has five approved drugs.
There are three US patents protecting RECKITT BENCKISER drugs.
Summary for Reckitt Benckiser
| US Patents: | 3 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
| Patent Litigation for Reckitt Benckiser: | See patent lawsuits for Reckitt Benckiser |
Drugs and US Patents for Reckitt Benckiser
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reckitt Benckiser | MUCINEX D | guaifenesin; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021585-002 | Jun 22, 2004 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Reckitt Benckiser | MUCINEX | guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021282-001 | Jul 12, 2002 | OTC | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Reckitt Benckiser | MUCINEX DM | dextromethorphan hydrobromide; guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021620-002 | Apr 29, 2004 | OTC | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Reckitt Benckiser | MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM | dextromethorphan hydrobromide; guaifenesin; naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 217338-001 | Dec 22, 2025 | OTC | Yes | Yes | 12,370,189 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Reckitt Benckiser
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Reckitt Benckiser | MUCINEX D | guaifenesin; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021585-002 | Jun 22, 2004 | 6,955,821 | ⤷ Start Trial |
| Reckitt Benckiser | MUCINEX DM | dextromethorphan hydrobromide; guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021620-001 | Apr 29, 2004 | 6,372,252 | ⤷ Start Trial |
| Reckitt Benckiser | MUCINEX | guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021282-002 | Dec 18, 2002 | 6,955,821 | ⤷ Start Trial |
| Reckitt Benckiser | MUCINEX | guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021282-001 | Jul 12, 2002 | 7,838,032 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for RECKITT BENCKISER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 600 mg and 1.2 gm | ➤ Subscribe | 2006-06-09 |
| ➤ Subscribe | Extended-release Suspension | 30 mg/5 mL | ➤ Subscribe | 2009-01-12 |
| ➤ Subscribe | Extended-release Tablets | 600 mg/30 mg and 1200 mg/60 mg | ➤ Subscribe | 2008-12-17 |
International Patents for Reckitt Benckiser Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3364955 | ⤷ Start Trial |
| United Kingdom | 201506755 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017062997 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016063057 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Reckitt Benckiser Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1539166 | 122013000090 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION AUS: (A) DEXTROMETHORPHAN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ, Z.B. DEXTROMETHORPHAN-HYDROBROMID UND INSBESONDERE DEXTROMETHORPHAN-HYDROBROMID-MONOHYDRAT; UND (B) CHINIDIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, Z.B.CHINIDIN-SULFAT UND INSBESONDERE CHINIDIN-SULFAT-DIHYDRAT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| 1539166 | 92323 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| 1539166 | SPC/GB13/070 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626 |
| 1539166 | 2013/055 | Ireland | ⤷ Start Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
